A B S T R AC T
Background. Proteinuria is a major predictor for progression of renal disease, including diabetic nephropathy. In a post hoc analysis of the ORIENT, a double-blinded randomized trial of 566 type 2 diabetic patients with nephropathy, we examined the risk association of composite renal outcome [end-stage renal disease, ESRD, doubling of serum creatinine (SCr) and death] with baseline, change and residual urinary protein/ creatinine ratio (UPCR). Methods. We estimated the hazard ratios (HRs) with 95% confidence interval (CI) of composite renal outcome with baseline UPCR (low <1.0 g/gCr; moderate ≥1.0 g/gCr, <3.0 g/ gCr and high ≥3.0 g/gCr) as well as percentage reduction of UPCR (Δ) (worsening: <0%; moderate: ≥0%, <30% and high ≥30%) and residual UPCR at 24 weeks (remission <1.0 g/gCr; moderate ≥1.0 g/gCr, <3.0 g/gCr and heavy ≥3.0 g/gCr). Results. Compared with the low group with baseline UPCR < 1.0g/gCr, the respective HRs with 95% CI in the moderate and high UPCR groups were 3.02 (1.76-5.19 ) and 9.24 (5.43-15.73 ). Compared with patients with a worsening UPCR (<0%) at 24 weeks, the HR was 0.54 (0.39-0.74) in those with ≥0%, <30% ΔUPCR and 0.43 (0.31-0.61) in those with ≥30% ΔUPCR. Compared with the remission at 24 weeks, the HR was 2.12 (1.28-3.49) in moderate residual proteinuria and 4.59 (2.74-7.69) in heavy residual proteinuria. Compared with patients with residual UPCR ≥1.0 g/gCr and ΔUPCR <30%, the HR in those with ΔUPCR≥30% and residual UPCR<1.0 g/gCr was 0.38 (0.22-0.64).
Conclusions. In patients with type 2 diabetes and overt nephropathy, over 30% reduction of UPCR compared with baseline and/or residual UPCR<1.0 g/gCr at 24 weeks predicted renoprotection. These values may be used as targets to guide anti-proteinuric and renoprotective therapy in diabetic nephropathy. Trial registration. ClinicalTrials.gov NCT00141453.
I N T RO D U C T I O N
Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) worldwide and 40-50% of ESRD is caused by diabetes [1] . In 2007, more than 15 000 Japanese had ESRD due to diabetes [2] . Landmark studies have confirmed that treatment with angiotensin II receptor blockers (ARBs) attenuated proteinuria, slow rate of decline of renal function and reduced incidence of ESRD [3, 4] in patients with diabetic nephropathy not receiving angiotensin-converting enzyme inhibitor (ACEI). In 2003, we conducted a double-blinded randomized controlled trial comparing olmesartan versus placebo in 577 type 2 diabetic patients with overt proteinuria (ORIENT: Olmesartan Reducing Incidence of ESRD in diabetic Nephropathy Trial) with 73% of patients receiving concomitant ACEI. The primary renal composite outcome included all-cause death, ESRD and doubling of serum creatinine (SCr). Treatment with olmesartan, an ARB, in addition to an ACEI, further reduced blood pressure (BP), urinary protein/creatinine ratio (UPCR) and rate of decline of renal function. It also reduced the secondary composite cardiovascular (CV) outcome but failed to reduce the primary composite renal outcome. Further analysis revealed that over 90% of the composite renal outcome occurred in patients with rapidly declining renal function which was not attenuated by olmesartan. However, in slow decliners, defined as the slope of reciprocal SCr (1/SCr) over time less than the median value, treatment with olmesartan slowed deterioration of renal function [5] .
Proteinuria is a strong predictor for future risk of chronic kidney disease (CKD) in patients with or without diabetes [6] . In the RENNAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) [7] and Irbesartan Diabetic Nephropathy Trial (IDNT) [8] , higher baseline proteinuria predicted adverse renal outcomes. In these type 2 diabetic patients with overt nephropathy, greater percentage reduction of proteinuria at 6-months also predicted better renal outcome [7, 8] . However, the effect size of percentage reduction of proteinuria and impact of remission of proteinuria had not been well established in diabetic nephropathy. Although widely recognized as a prognostic biomarker, whether proteinuria can serve as a surrogate marker for CKD and ESRD remained debatable [6] . In this context, the US Food and Drug Administration did not accept effects on proteinuria as evidence of drug effectiveness due to insufficient evidence to support its causal role in ESRD [9] .
In this analysis, we studied the impacts of degree of UPCR at baseline, percentage reduction of UPCR (ΔUPCR) and remission of nephropathy defined as UPCR <1.0 g/gCr at 24-weeks on the composite renal outcome in the ORIENT.
M E T H O D S
Patients and study design The ORIENT was a multicenter, randomized, doubleblinded trial that compared the effects of olmesartan versus placebo in patients with type 2 diabetes and overt nephropathy receiving contemporary medications including ACEIs. We screened 857 patients and enrolled 377 patients from Japan and 200 patients from Hong Kong with the following inclusion criteria: (1) age between 30 and 70 years; (2) urinary albumin/creatinine ratio (UACR) >300 mg/gCr in the first morning urine sample; (3) SCr concentration of 1.0-2.5 mg/dL in female and 1.2-2.5 mg/dL in male (normal range <1.0 mg/dL). The major exclusion criteria included (i) type 1 diabetes; (ii) history of myocardial infarction or coronary artery bypass grafting (CABG) within 3 months prior to consent; (iii) percutaneous coronary intervention, carotid artery or peripheral artery revascularization within 6 months; (iv) stroke or transient ischaemic attack (TIA) within 1 year; (v) unstable angina pectoris or heart failure of New York Heart Association functional Class III or IV; (vi) rapidly progressive renal disease within 3 months prior to consent; (vii) severe orthostatic hypotension and (viii) serum potassium level ≤3.5 mEq/L or ≥5.5 mEq/L. This study was conducted with adherence to Good Clinical Practice (GCP) and the Declaration of Helsinki. All patients provided signed informed consent. Eligible patients were randomly assigned to receive either 10 mg of olmesartan once-daily or placebo. If the target BP <130/ 85 mmHg was not achieved 4 weeks after randomization or at any time thereafter, the dose of olmesartan was increased to 20 mg daily (or placebo), with further titration to 40 mg (or placebo), upon which additional antihypertensive agents could be used. These included diuretics, beta-blockers, calcium channel blockers and alpha-blockers. Every reasonable attempt was made to up-titrate the test drug to the maximum dose, even if the target BP was achieved. The use of potassium-sparing diuretics or ARB was prohibited and addition of an ACEI after enrolment was not allowed. Patients treated with ACEIs at baseline had to continue with the same dosage throughout the study. Eleven patients were excluded from the final analysis due to protocol violation from the viewpoint of GCP. Among the analysed patients (n = 566), 282 received olmesartan and 284 received placebo in addition to conventional antihypertensive therapy.
The primary composite renal outcome was doubling of SCr, ESRD (SCr>5 mg/dL, chronic dialysis, transplantation) and all-cause death. SCr was measured at a central laboratory in Japan (SRL, Inc. Tokyo, Japan). One of the secondary outcomes was percentage reduction in UPCR at 24 weeks.
Measurement
In this post hoc analysis, we focused on the risk association of baseline, change and residual proteinuria with the composite renal outcome. Proteinuria was assessed using the ratio of proteinuria (g/dL) to creatinine (g/dL) concentration (UPCR) measured in a random spot urine sample collected at baseline and every 3 months after randomization throughout the study. None of the enrolled patients had missing values of proteinuria at baseline. For patients with missing values at 24 weeks, the last observed value was carried forward.
Statistical analysis
The pre-specified primary analysis had been described [5] . Consistent with the pre-specified analysis, post hoc analysis included all 566 randomized and eligible participants in the ORIENT. We conducted univariate and multivariate Cox regression analyses with adjustment for confounding factors. These included region, SCr, age, gender, baseline UPCR, systolic/diastolic BP, HbA1c, and previous CV disease. On multivariate analysis, factors were selected by the backward elimination method (P < 0.05 for retention) starting with the full model including all factors. We used the Kaplan-Meyer analysis to explore the association of composite renal outcome with baseline UPCR divided into three categories: low, <1.0 g/gCr; moderate, ≥1.0 g/gCr, <3.0 g/gCr; high, ≥3.0 g/gCr. The multivariate Cox regression model was applied to estimate the hazard ratio (HR) with 95% confidence intervals (CIs) using patients with <1.0 g/gCr as the referent group. We further explored the risk association of renal composite outcome with treatment responses using two analyses. First, we explored the association between ΔUPCR at 24 weeks compared with baseline divided into three categories: worsening, <0%; moderate, ≥0%, <30%; and high, ≥30% using the Cox regression model with Δ≥30% as the referent group. Second, we explored the risk association with residual UPCR at 24 weeks divided into three groups: heavy, ≥3.0 g/gCr; moderate, ≥1.0 g/gCr, <3.0 g/gCr and remission, <1.0 g/gCr. The Cox regression model with the same covariates and systolic BP change at 24 weeks were applied using the remission group as the referent group. To search for the threshold values of ΔUPCR and residual UPCR at 24 weeks where the risk of composite renal outcomes started to accelerate, we plotted the percentages of the composite renal outcomes for ΔUPCR or residual UPCR at 24 weeks by a moving average method [10] . The Cox regression model with the same covariates and systolic BP changes at 24 weeks were applied to estimate the HR among UPCR reduction rate (Δ≥30% or not) and residual UPCR (<1.0 g/gCr or not) at 24 weeks.
We also divided patients into those with the rate of change of 1/SCr greater (slow decliner) or less than the median (rapid decliner) and plotted the ΔUPCR from baseline during the study period stratified by treatment groups.
All values were expressed as mean ± SD or median (interquartile range, IQR) as appropriate. All statistical tests were two-sided with 0.05 significance level. Statistical analyses were performed using Statistical Analysis System version 9.2 (SAS Institute, Cary, NC).
R E S U LT S

Study population
At enrolment, the mean age of the participants was 59.2 years, 69.1% were male and 73.1% were treated with ACEIs.
The mean values of systolic/diastolic BP were 141.3/77.5 mmHg and SCr, 1.62 mg/dL. The median of UPCR and UACR were 2.10 g/gCr and 1.70 g/gCr, respectively. The clinical profiles of patients randomized to olmesartan and placebo were similar [5] . In this analysis, which focused on risk association with proteinuria, the clinical profiles were similar among patients stratified by ΔUPCR (<0%; ≥0%, 30%; and ≥30%) at 24 weeks (Table 1) . After a mean follow-up period of 3.2 years, 245 patients developed the composite renal outcome.
Risk factors, baseline UPCR and renal outcomes
We conducted univariate and multivariate Cox regression analyses with potential confounding factors. On multivariate analysis, high SCr, high systolic BP, high baseline UPCR, low total cholesterol, low blood haemoglobin and enrolment in Japan were associated with increased HR of composite renal outcome ( Table 2 ). At baseline, there were 194 patients in the high proteinuria group (≥3.0 g/gCr), 236 in the moderate (≥1.0 g/gCr, < 3.0 g/gCr) and 136 in the low group (<1.0 g/ gCr). Compared with the low group, the respective HR with 95% CI was 3.02 (1.76-5.19, P < 0.001) in the moderate group and 9.24 (5.43-15.73, P < 0.001) in the high proteinuria group (Figure 1 ). The effects of baseline UPCR on the renal outcome were similar between the olmesartan and placebo groups (data not shown).
Reduction in UPCR at 24 weeks and renal outcome After 24 weeks of treatment, 170 had high reduction (≥30% ΔUPCR), 134 had moderate reduction (≥0%, <30%) and 262 had worsening proteinuria (<0%), who had similar characteristics at baseline (Table 1) . Compared with the worsening group, the HR with 95% CI for the composite renal outcome was 0.43 (0.31-0.61, P < 0.001) in patients with high reduction and 0.54 (0.39-0.74, P < 0.001) in those with moderate reduction (Figure 2) . The results were similar between patients treated with olmesartan and placebo (data not shown). The respective median (IQR) of slope of 1/SCr were −0.044 (−0.091, −0.019), −0.099 (−0.151, −0.048) and −0.101 (−0.178, −0.056) dL/mg/year in patients with ≥30%, 0-30% and <0% ΔUPCR (P < 0.001). Figure 3 shows the relationship between percentages of composite renal outcomes versus ΔUPCR reduction which showed a negative relationship from a ΔUPCR of 30% onwards.
Remission of UPCR and renal outcomes At 24 weeks, 201 patients had heavy (≥3.0 g/gCr) and 207 had moderate residual UPCR (≥1.0 g/gCr, <3.0 g/gCr), while 158 had remission of nephropathy (<1.0 g/gCr). Compared with the remission group, the respective HRs with 95% CIs of the moderate and heavy residual UPCR groups were 2.12 (1.28-3.49, P = 0.003) and 4.59 (2.74-7.69, P < 0.001) (Figure 4 Baseline, reduction and residual UPCR and renal outcomes In patients with baseline UPCR≥1.0 g/g Cr, HR with 95% CI was 0.56 (0.40-0.78, P < 0.001) in those with ΔUPCR≥30% compared with those with ΔUPCR < 30%. In patients with baseline UPCR<1.0 g/gCr, the HR with 95% CI was 0.41 (0.12-1.41, P = 0.157). Compared with patients with residual UPCR≥1.0 g/gCr and ΔUPCR < 30%, the respective HRs with 95% CIs in those with ΔUPCR≥30% and residual UPCR < 1.0 g/gCr (remission), those with ΔUPCR≥30% but residual UPCR≥1.0 g/gCr and those who achieved remission 
<0.001
Data are expressed as means ± SD or n (%).
a Median (interquartile range). b The value for HbA1c (%) is estimated as an NGSP equivalent value (%) calculated by the formula HbA1c (%) = HbA1c (JDS)(%) + 0.4%, considering the relational expression of HbA1c (JDS)(%) measured by the previous Japanese standard substance and measurement methods and HbA1c (NGSP).
O R I G I N A L A R T I C L E
T a r g e t i n g p r o t e i n u r i a i n d i a b e t i c n e p h r o p a t h y but had ΔUPCR < 30% were 0.38 (0.22-0.64, P < 0.001), 0.59 (0.40-0.86, P = 0.007) and 0.25 (0.10-0.61, P = 0.003) ( Figure 6 ).
Rate of decline of renal functions and renal outcomes
Olmesartan significantly reduced UPCR at 24 weeks (olmesartan, −19.3%; placebo, +5.1%) and during follow-up (olmesartan, −21.4%; placebo, +7.7%, P = 0.005). Among the rapid decliners defined as slope of 1/SCr less than the median value, baseline UPCR were 3.35 g/gCr in the olmesartan group and 3.51 g/gCr in the placebo group. Placebo increased UPCR at 24 weeks (olmesartan, −5.2%; placebo, +16.8%) and during follow-up (olmesartan, +7.6%; placebo, +27.7%, P = 0.002). On the other hand, among the 305 slow decliners, baseline UPCR were 1.12 g/gCr in the olmesartan group and 1.27 g/ gCr in the placebo group. Olmesartan significantly reduced UPCR at 24 weeks (olmesartan, −32.9%; placebo, −3.3%) and during follow-up (olmesartan, −41.1%; placebo, −4.1%, 
Cumulative event rate of composite renal outcome stratified by baseline UPCR. Kaplan-Meier analysis of time to composite renal outcome in type 2 diabetic patients with overt proteinuria and renal insufficiency. Patients were divided into three groups by baseline UPCR: high (≥3.0 g/gCr), moderate (≥1.0 g/gCr, <3.0 g/gCr) and low (<1.0 g/gCr). The HR was estimated by the Cox regression analysis with SCr, regions (Japan/Hong Kong), blood haemoglobin, systolic BP and total cholesterol as covariates.
P < 0.001, Figure 7 ). In the olmesartan group, the composite renal outcome occurred in eight patients (5.7%) and 108 patients (76.6%) in the slow and rapid decliner groups, respectively, with HRs compared with the placebo group of 0.61 (0.25-1.46, P = 0.265) and 1.00 (0.77-1.30, P = 0.999) ( Table 3) .
D I S C U S S I O N
In this post hoc analysis of the ORIENT involving type 2 diabetic patients with overt nephropathy, baseline, change and residual UPCR all predicted composite renal outcome. Either more than 30% of reduction or remission of UPCR to <1.0 g/gCr at 24 weeks significantly improved the renal outcome. In contrast, patients with worsening and/or more than 1 g/gCr of residual proteinuria had higher risk of renal outcome compared with those who responded with remission of nephropathy. These results suggested that reducing UPCR is an independent predictor from BP change since the HR was adjusted for BP change at 24 weeks. Together with other experimental and clinical studies, these results strongly support the notion that occurrence of ESRD was highly dependent on the proteinuric status and their response to antiproteinuric treatments. For the first time, we have demonstrated that reducing UPCR by at least 30% and/or targeting a residual UPCR to <1.0 g/gCr might be used as therapeutic targets in the prevention of progression of nephropathy in type 2 diabetes. In a meta-analysis of 13 CKD cohorts, baseline proteinuria was an independent and strong risk factor for developing ESRD [11] . In RENAAL, increased albuminuria at baseline was associated with increased risk for renal outcome [7, 12] . In IDNT, there was a doubling of risk for progression to ESRD with each doubling of baseline proteinuria [8] . In patients with non-diabetic kidney disease, baseline proteinuria >3 g/day was associated with a more rapid rate of decline of SCr [13] . While these findings emphasize the importance of proteinuria and its changing status in predicting the renal outcome, the magnitude of reduction and attained value of proteinuria to achieve renoprotection have not been well defined in diabetic or nondiabetic kidney disease.
In RENAAL, patients with ≥30% reduction of proteinuria at 6 months had 39% relative risk reduction in the renal outcome compared with those with 0-30% of reduction [7] . In IDNT, patients with >50% reduction in proteinuria at 12 months reduced the risk of ESRD by 56% [8] . In the ONgoing Telmisartan Alone and in combination with Ramipril Global F I G U R E 3 : The pattern plot for the percentages and 95% CI of composite renal outcome for percentage reduction in UPCR at 24 weeks compared with baseline. Each plotted percentage of outcomes is calculated with patients whose percentage reduction in UPCR at 24 weeks in the interval between −20% and +20% of each reduction.
Cumulative event rate of composite renal outcome stratified by percentage reduction (Δ) in UPCR at 24 weeks compared with the baseline value. Kaplan-Meier analysis of time to composite renal outcome in type 2 diabetic patients with overt proteinuria and renal insufficiency. All patients were divided into three groups by ΔUPCR at 24 weeks: high reduction (≥30%), moderate reduction (≥0%, <30%) and worsening group (<0%). HR was estimated by the Cox regression analysis with SCr, regions (Japan/Hong Kong), blood haemoglobin, baseline systolic BP, baseline UPCR, total cholesterol and systolic BP change at 24-weeks as covariates.
Endpoint Trial (ONTARGET), 50% reduction in albuminuria reduced the composite renal outcome by 27%, although only 10% of patients had 30 mg/gCr of albuminuria in this study [14] . In this post hoc analysis of the ORIENT, using a full range of values, we observed that the rate of renal outcomes started to decline from 30% ΔUPCR with a near linear negative relationship thereafter.
Apart from reducing proteinuria, the impact of residual proteinuria achieved by reducing BP or inhibiting the reninangiotensin system inhibitor has not been well studied in diabetic nephropathy. In RENAAL, there was a linear relationship between the degree of residual proteinuria at 6 months and the renal outcome [7] . In non-diabetic renal disease, such as IgA nephropathy [15] and idiopathic membranous nephropathy [16] , patients with sustained reduction of proteinuria to <1.0 g/day had an excellent prognosis regardless of initial proteinuria. Interestingly, 30% reduction in proteinuria and achieving a residual UPCR <1.0 g/gCr (equivalent to ∼0.6 g/ gCr of UACR) independently conferred renoprotection. These findings suggested that these values may be used to guide anti-proteinuric therapy in type 2 diabetic patients with overt nephropathy. The linear relationship between these target values and event rates suggested the lower levels of UPCR achieved and greater reduction in UPCR; hence, the better renal protection might be expected. However, side effects, notably excessive lowering of BP and hyperkalaemia, F I G U R E 5 : The pattern plot for the percentages and 95% CI of the composite renal outcome for residual UPCR at 24 weeks. Each plotted percentage of outcomes is calculated with patients whose residual UPCR are in the interval between -0.5 and +0.5 of each value (log scale).
F I G U R E 6 : HRs of composite renal outcomes stratified by UPCR at 24 weeks and percentage reduction (Δ) at 24 weeks compared with baseline. Patients were stratified by residual UPCR and ΔUPCR and using patients with residual UPCR<1.0 g/gCr and/or ΔUPCR≥30% as reference, the HRs and 95% CI for composite renal outcomes were estimated by the Cox regression analysis with SCr, regions (Japan/Hong Kong), blood haemoglobin, systolic BP, baseline UPCR, total cholesterol and systolic BP change at 24-weeks as covariates.
Cumulative event rate of composite renal outcome stratified by residual UPCR at 24-weeks. Kaplan-Meier analysis of time to primary renal composite endpoint in type 2 diabetic patients with overt proteinuria and renal insufficiency. All patients were divided into three groups by residual UPCR at 24 weeks: heavy (≥3.0 g/gCr), moderate (≥1.0 g/gCr, <3.0 g/gCr) and remission group (<1.0 g/gCr). HR was estimated by the Cox regression analysis with SCr, regions (Japan/Hong Kong), blood haemoglobin, baseline systolic BP, baseline UPCR, total cholesterol and systolic BP change at 24 weeks as covariates. must be taken into consideration. In ORIENT, none of the patients developed acute renal failure in the first 6 months of intensive therapy [5] .
Using surrogate endpoints in clinical trials is attractive since this will entail smaller sample size and shorter duration of intervention with major cost implications. Doubling of SCr has been used as a surrogate for ESRD [17] . Landmark studies have indicated that 30-50% reduction in albuminuria or more at 6 months conferred long-term renoprotection [7, 8, 18] . In this post hoc analysis, we have confirmed these findings and further showed that apart from reducing UPCR by ≥30%, achieving a residual UPCR <1.0 g/gCr at 24 weeks had additive effects on renoprotection [9] , which can be used as an indicator to guide antiproteinuric and renoprotective therapies.
The renoprotective effect of olmesartan was the primary hypothesis in the ORIENT. Although we failed to demonstrate the effects of olmesartan on the composite renal outcome, olmesartan significantly reduced the average difference in UPCR during follow-up by −21.4%, while placebo increased by +7.7%, (P = 0.005). Furthermore, 41.8% of patients had ≥30% reduction in UPCR in the olmesartan group, 73% of whom were receiving concomitant ACEIs, compared with 18.3% in the placebo group. However, the majority of the composite renal outcomes were obtained in the rapid decliner group, despite treated with olmesartan. In patients treated with olmesartan, the UPCR increased by +7.6% in the rapid decliner group, while reduced by −41.1% in the slow decliner group. These findings may suggest that the faster the declining rate of GFR, the more the proteinuria in type 2 diabetic patients, and the less response to ARB.
The major limitation of this analysis was the post hoc nature. That said, the data collection was nearly complete during this 3.2-year study with every patient being followed up 3-monthly and only four patients were lost to follow-up. Baseline and 3-monthly proteinuria and albuminuria were measured at a central laboratory. In analyses stratified by a treatment-induced change, with breaking the randomized controlled design the risk factors could be subjected to confounding.
In conclusion, 30% reduction in proteinuria and/or attaining a residual proteinuria of <1.0 g/gCr was associated with renoprotection in patients with type 2 diabetes and over nephropathy.
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